WHO WE ARE
Healing Without Harm.
For too long, the journey through cancer treatment has been defined by a difficult compromise: accepting harsh, often debilitating side effects in the pursuit of a cure. Patients have been asked to endure not just the disease, but the trauma of its treatment.
At Orbicure, we believe there is a better way. Our lead therapy is engineered to precisely target a life-threatening complication of cancer without causing systemic harm, resolving the historic conflict between a drug's power and a patient's quality of life. We are creating a future where healing is a restorative process, not a destructive one.
Increased mortality for cancer patients who develop a VTE.
2nd
Leading cause of death in many cancers, after the cancer itself.
Of all cancer-related deaths are attributable to VTE.
The Unseen Risk in Cancer Care
For patients fighting cancer, the battle is often compounded by a silent but deadly threat: venous thromboembolism (VTE), or blood clots.
OUR SCIENCE
Data-Driven Solutions, Designed for Life.
Our innovation begins with the elegant wisdom of nature. The flavonoid at the heart of our platform is a naturally derived compound, providing a powerful and proven foundation for our science. But our work doesn't stop there. Through rigorous pharmacology and data-driven development, we transform this natural potential into precision-engineered medicine, creating therapies that are both intelligent and human.
KINISOQUIN™
Precision, Protection, and Peace of Mind.
Our lead candidate, Kinisoquin™, represents a new orbit of therapy. It is a novel, proprietary formulation designed to inhibit Protein Disulphide Isomerase (PDI), a key enzyme that initiates the dangerous cascade of thrombo-inflammation.Unlike traditional anticoagulants, its action is precise and localized. It selectively blocks PDI activity at the site of vascular injury, preventing clots from forming without systemically altering the body's essential coagulation functions. This targeted approach is the key to its exceptional safety profile.
"Developing an effective and safe antithrombotic agent would greatly improve adoption of primary prevention strategies in the cancer community. The primary concern with currently available anticoagulants is the increased risk of hemorrhage."
Jeffrey Zwicker, MD
Professor of Medicine, Memorial Sloan Kettering Cancer Center (MSK)
LEARN MORE
OUR PARTNERS
Data-Driven Solutions, Designed for Life.
OUR MISSION
Broad Applications, One Healing Goal.
Our journey begins with one of the most urgent needs in oncology: preventing life-threatening thrombosis in cancer patients. But the potential of our platform is far-reaching. With promising applications in Sickle Cell Disease, Amyotrophic Lateral Sclerosis (ALS), and other complex conditions, we are pursuing a broad pipeline guided by a singular mission: to bring our transformative science to every patient we can possibly help.
OUR TEAM
A World-Class Team for a Global Mission.
Executing a mission of this scale requires leadership with deep experience, global perspective, and unwavering dedication.
Leadership
Thomas Lines
CEO
Jerzy Meduski
VP of Drug Development
Dr. Stefan Wohlfeil
Senior Advisor
Dr. Yves Grumser
Chief Medical Officer
Richard O'Neil
Chief Legal Officer
Scientific Advisory Board
Our strategy is informed and validated by global leaders in oncology, hematology, and neurodegenerative disease.
Dr. Jean Pierre Bizzari
CMO of Cellgene, Chairman of EORTC New Drug Advisory Committee
Dr. Louis Barbeito
Laboratory of Neurodegeneration at Pasteur Institute in Uruguay
Dr. Manuel Hildalgo
Chief of the Division of Haematology and Medical Oncology at the Weill Department of Medicine, Cornell University
Prof. Dr. Simone Schürle-Finke
Professor at ETH Zurich
VIEW FULL TEAM
CONTACT US
A World-Class Team for a Global Mission.
Executing a mission of this scale requires leadership with deep experience, global perspective, and unwavering dedication.
